Sp1276
PARTNERING WITH PATIENTS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS USING AN ORAL PRESCRIPTION THERAPY
Date
May 7, 2023
Society: DDW
Dr. Bincy Abraham and Gabriella McCarty, NP, will discuss proactive patient involvement in shared decision-making by incorporating a case-based approach within the clinical overview of an oral prescription therapy for moderate-to-severe ulcerative colitis. Sponsored by Pfizer
Dr. Bincy Abraham and Gabriella McCarty, NP, will discuss proactive patient involvement in shared decision-making by incorporating a case-based approach within the clinical overview of an oral prescription therapy for moderate-to-severe ulcerative colitis. Sponsored by Pfizer
Presenter
Houston Methodist
Speaker
Tracks
Related Products
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
IBD Complications
This session will examine the outcomes of a spectrum of IBD related complications including colon cancer. It will also examine cost and efficient care delivery…
